SCI

5Apr

Pembrolizumabinpatientswithnon-small-celllungcancerofperformancestatus2(PePS2):asinglearm,phase2trial

MiddletonGary,BrockKristian,SavageJoshuaetal.Pembrolizumabinpatientswithnon-small-celllungcancerofperformancestatus2(PePS2):asinglearm,phase2trial.[J].LancetRespirMed,,undefined:undefined.

Background背景

Therapeuticblockadeoftheaxisofprogrammedcelldeath1(PD-1)anditsligand(PD-L1)hastransformedthemanagementofnon-small-celllungcancer(NSCLC).Clinicaltrialswithpembrolizumabhaveenrolledpatientswithperformancestatus(PS)0–1.However,around18%ofpatientswithNSCLCarePS2,andtheactivityandsafetyofpembrolizumabinthesepatientsisunclear.Weaimedtoevaluatethesafetyandefficacyofpembrolizumabinthesepatients.

程序性细胞死亡1轴(PD-1)及其配体(PD-L1)的治疗阻断改变了非小细胞肺癌(NSCLC)的治疗。帕博利珠单抗的临床试验已经招募了体力状态(PS)为0-1的患者。然而，大约18%的非小细胞肺癌患者是PS2，帕博利珠单抗在这些患者中的活性和安全性尚不清楚。我们的目的是评估帕博利珠单抗在这些患者中的安全性和有效性。

Methods方法

Wedidamulticentre,single-arm,open-label,phase2trial(PePS2)intenhospitalsintheUK,inwhichpatientswithNSCLCandarigorousascriptionofPS2weregivenpembrolizumabmgevery3weeks.Nomaskingwasusedinthistrial.Westratifiedthetreatmentevaluationbytumourproportionscore(TPS)andlineoftherapy.Co-primaryout